Test Predicts Which CRC Patients Benefit from Adjuvant Chemo

Testing for molecular residual disease was able to identify patients with early-stage colorectal cancer who are most likely to benefit from adjuvant chemotherapy.

Related Keywords

Japan ,United States ,Washington ,Thomasj George Jr ,Takayuki Yoshino ,Benjamin Weinberg ,Alexey Aleshin ,Natera Inc ,National Cancer Center Hospital ,Gi Oncology Program ,University Of Florida ,Georgetown University Lombardi Comprehensive Cancer Center ,Japan Agency For Medical Research ,Division Of Hematology ,Cancers Symposium ,Medscape Medical News ,Medscape Medical ,National Cancer Center Hospital East ,Georgetown University ,Lombardi Comprehensive Cancer Center ,Japan Agency ,Medical Research ,Pfizer Oncology ,Colorectal Cancer ,Adjuvant Chemotherapy ,Chemotherapy ,Biologic Therapy ,Cancer ,Alignant Neoplasia ,Arcinoma ,Colon Cancer ,Alignant Colon Neoplasm ,Surgery ,Residual Disease ,Disease Recurrence ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Ealth And Medical Technology ,Immunotherapy ,Tumor ,Practice Management ,Adjuvant Therapy ,Antigens ,Clinical Research ,Linical Tri ,